newsfilter
← Latest News
GlobeNewswire·

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing expansion studyTopline